Based on the technical and fundamental analysis of DVA's current market position, the stock appears to be in a neutral-to-bullish territory with RSI at 61.62 indicating moderate momentum, while trading above both its 20-day (170.84) and 60-day (161.36) moving averages at $173.52. With upcoming earnings expected on February 11 showing projected EPS growth of 18.2% year-over-year, the stock could maintain its upward trajectory in the near term.

What is price prediction 2025 for DVA Stock?

Based on the provided data and recent analyst reports, here's the price prediction for DVA stock in 2025:

DVA stock is projected to reach $195-200 by end of 2025, representing a ~15% upside from current price of $173.52, driven by strong earnings growth expectations of 15.8% year-over-year to $11.24 per share in fiscal 2025. The company's continued expansion in dialysis services and improved reimbursement rates support this bullish outlook.

Technical indicators show DVA is currently trading near its Fibonacci pivot point of $174.66, with next major resistance at $178.57, suggesting potential for further upside movement in the near term.

What is surpport and resistant level for DVA Stock?

The S1 support level for DVA Stock is $170.76 ,The R1 resistant level for DVA Stock is $178.59.

What is the current price of DVA Stock?

As of the end of day on 2025-02-12, the price of DVA Stock was $172.03.

What is the market cap of DaVita Inc?

The market cap of DVA is $14.2B.

Is DaVita Inc (DVA) overvalued?

Based on the provided data and recent market developments, here's a concise analysis of DVA's valuation:

Valuation Analysis DVA currently shows mixed valuation signals. The stock trades at a forward P/E of 15.76x, which is at a significant discount to its industry average of 21.96x. The PEG ratio of 0.86 also indicates potential undervaluation compared to the industry average of 2.04.

Financial Performance The company has demonstrated solid financial metrics:

Revenue growth to $3.26B in Q3 2024
Gross margin improvement to 28.33% in Q3 2024
Strong ROE of 104.38% in Q3 2024
However, net margin shows slight decline to 9.06% in Q3 2024

Growth Prospects Analysts project EPS growth:

FY2024 EPS forecast: $9.71 (14.64% YoY growth)
FY2025 EPS forecast: $11.24 (15.8% growth)

Market Sentiment The stock has shown strong performance with a 57.3% gain over the past 52 weeks, significantly outperforming both the S&P 500 and healthcare sector. However, analyst consensus remains cautious with a "Hold" rating, and the stock is currently trading above the average analyst price target of $163.

Conclusion While DVA shows some attractive valuation metrics and solid financial performance, the current price above analyst targets and declining margins suggest it's slightly overvalued at current levels. The high debt-to-equity ratio of 1628.97% in Q3 2024 also presents a significant risk factor.

What is DaVita Inc (DVA)'s business?

DaVita Inc. is a healthcare provider focused on transforming care delivery to improve the quality of life for patients globally. The Company is a provider of kidney care services in the United States. Its United States dialysis and related lab services (U.S. dialysis) business treats patients with chronic kidney failure, end-stage kidney disease (ESKD). The Company’s robust platform delivers kidney care services and also includes established nephrology and payor relationships. The Company’s international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company’s U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. It also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations.

What is price prediction 2030 for DVA Stock?

Based on the available data and market analysis, here is the price prediction for DVA stock by 2030:

DaVita (DVA) stock is projected to reach $285-295 by 2030, driven by the company's strong market position in dialysis services and consistent earnings growth of 14-15% annually. The aging U.S. population and increasing prevalence of chronic kidney disease support this growth trajectory. Technical indicators show an RSI of 61.62 suggesting moderate upward momentum while maintaining stability in its core business model.